Design and Development of Novel Mini Tablet Cap Technology for the Treatment of Cardiovascular Diseases

Abstract

Objectives: The purpose of the investigation was to extend and evaluate the novel mini tablet cap for treating cardiovascular disease at a desired combinational therapeutic activity and to improve patient compliance. A cheap four-in-one pill can guard against heart attacks and stroke. Methods and Materials: The drug product was manufactured by mini tablet cap technology. The technology was designed to initially use hydrochlorothiazide, simvastatin immediate release, metoprolol succinate, and asprin sustained release to reach the therapeutic levels at prolonged therapy. The two mini-bilayer tablets were prepared by wet granulation method and compression coated with a hydrophobic and hydrophilic polymer like ethyl cellulose and super disintegrating agents to release simvastatin and hydrochlorothiazide immediately. Results: Fourier transformer infrared spectroscopy (FTIR) studied the interaction studies of four chosen drugs. The mini tablet cap technology was designed as two mini bi-layer tablets in a capsule. The quantitative detection of four individual drugs was determined by using the RP-HPLC method. It was found that RP-HPLC is sensitive, reproducible, and valid for determining the mini tablet cap. The in-vitro drug release studies found that simvastatin and hydrochlorothiazide release 90% immediately within 20 minutes. Metoprolol and aspirin controlled the release for up to 24 hours, and drug release kinetics found that the drug release behavior of the optimized formulation followed first-order kinetics. Conclusion: The mini tablet cap is one of the best dosage forms to treat cardiovascular diseases. Because it was reported, the combination of these four drugs reduces mortality by 83% in high-risk patients with heart diseases, hypertension, diabetes, and obesity. The novel mini tablet cap approach data revealed a promising formula for improved relief of patient complaints during treatment or prevention of cardiovascular diseases